Sanofi and CD&R Negotiate Sale of 50% Stake in Opella

Sanofi and private equity firm CD&R (Clayton, Dubilier & Rice) announced exclusive negotiations for the sale of a 50% controlling stake in Opella. Sanofi would remain a significant shareholder if the transaction is finalized.

The proposed transaction is intended to establish Opella as a standalone global consumer healthcare company, supporting Sanofi's strategic shift towards innovative medicines and vaccines. Opella, which employs approximately 11,000 people and manages brands such as Allegra and Doliprane, currently ranks as the third-largest global player in over-the-counter and vitamin markets.

The company's valuation is set at an enterprise value of approximately €16 billion. Completion is anticipated in the second quarter of 2025, pending definitive agreements, social procedures, and customary regulatory approvals. Bpifrance is also expected to join as a minority shareholder with about a 2% stake.

CD&R has prior experience in supporting business growth and has invested in French companies. They cite Opella's brand portfolio and skilled workforce as key drivers for potential expansion. Sanofi aims for this move to enable a stronger focus on its biopharmaceutical research and development.